PepGen 2023 - Meet the DM Drug Developers

Each month biotechnology, pharmaceutical and academic partners, large and small, working on treatments and a cure for myotonic dystrophy will sit down with our community to share their progress and answer your questions.
Learn more about PepGen at pepgen.com/
Speakers Include:
+ Jane Larkindale, Vice President of Clinical Science
+ Stephen Babcock, Senior Clinical Project Manager
+ Ashling Holland, Director of Preclinical Development
+ Jenny Shoskes, PharmD, Associate Director of Clinical Development
Find all our upcoming Meet the DM Drug Developers dates at www.myotonic.org/meet-dm-drug...
0:00:00 - Introduction
0:06:20 - About PepGen & PGN-EDODM1
0:13:20 - Learnings from Pre-clinical Models
0:22:59 - Starting a Clinical Trial
0:29:47 - Designing a Clinical Trial
0:37:20 - Community Engagement
0:43:17 - Where to learn more about FREEDOM-EDODM1
0:44:39 - Q&A

[@PDsWorship]

This study/clinical trial seems to be looking for outcomes on reducing myotonia symptoms. IE. Measuring muscle relaxation times
Will there be any intentional focus on reducing the dystrophy side? IE. Regaining or growing muscle fiber.